

E V Mccloskey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7265771/publications.pdf>

Version: 2024-02-01

486
papers

45,907
citations

1893

102
h-index

2280

200
g-index

505
all docs

505
docs citations

505
times ranked

25812
citing authors

#	ARTICLE	IF	CITATIONS
1	FRAX [®] and the assessment of fracture probability in men and women from the UK. <i>Osteoporosis International</i> , 2008, 19, 385-397.	3.1	2,017
2	Osteoporosis in the European Union: medical management, epidemiology and economic burden. <i>Archives of Osteoporosis</i> , 2013, 8, 136.	2.4	1,932
3	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. <i>Osteoporosis International</i> , 2013, 24, 23-57.	3.1	1,560
4	Body mass index as a predictor of fracture risk: A meta-analysis. <i>Osteoporosis International</i> , 2005, 16, 1330-1338.	3.1	1,292
5	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. <i>Nature Genetics</i> , 2012, 44, 491-501.	21.4	1,100
6	A meta-analysis of previous fracture and subsequent fracture risk. <i>Bone</i> , 2004, 35, 375-382.	2.9	1,052
7	A systematic review of hip fracture incidence and probability of fracture worldwide. <i>Osteoporosis International</i> , 2012, 23, 2239-2256.	3.1	1,048
8	The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. <i>Osteoporosis International</i> , 2007, 18, 1033-1046.	3.1	1,017
9	A reference standard for the description of osteoporosis. <i>Bone</i> , 2008, 42, 467-475.	2.9	929
10	Smoking and fracture risk: a meta-analysis. <i>Osteoporosis International</i> , 2005, 16, 155-162.	3.1	755
11	A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 893-899.	2.8	666
12	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 518-530.	2.8	617
13	UK clinical guideline for the prevention and treatment of osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 43.	2.4	609
14	FRAX [®] and its applications to clinical practice. <i>Bone</i> , 2009, 44, 734-743.	2.9	605
15	Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. <i>Journal of Clinical Oncology</i> , 1993, 11, 59-65.	1.6	563
16	Osteoporosis in the European Union: a compendium of country-specific reports. <i>Archives of Osteoporosis</i> , 2013, 8, 137.	2.4	561
17	Case finding for the management of osteoporosis with FRAX [®] assessment and intervention thresholds for the UK. <i>Osteoporosis International</i> , 2008, 19, 1395-1408.	3.1	520
18	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 940-948.	2.8	508

#	ARTICLE	IF	CITATIONS
19	The assessment of vertebral deformity: A method for use in population studies and clinical trials. <i>Osteoporosis International</i> , 1993, 3, 138-147.	3.1	503
20	Pitfalls in the measurement of muscle mass: a need for a reference standard. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 269-278.	7.3	482
21	Osteoporosis: burden, health care provision and opportunities in the EU. <i>Archives of Osteoporosis</i> , 2011, 6, 59-155.	2.4	459
22	Interpretation and use of FRAX in clinical practice. <i>Osteoporosis International</i> , 2011, 22, 2395-2411.	3.1	450
23	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 223-233.	2.8	388
24	Burden of high fracture probability worldwide: secular increases 2010–2040. <i>Osteoporosis International</i> , 2015, 26, 2243-2248.	3.1	382
25	Fragility fractures in Europe: burden, management and opportunities. <i>Archives of Osteoporosis</i> , 2020, 15, 59.	2.4	369
26	Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3219-3224.	1.6	362
27	Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. <i>Bone</i> , 2015, 78, 216-224.	2.9	362
28	Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). <i>Osteoporosis International</i> , 1999, 10, 150-160.	3.1	346
29	Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. <i>Maturitas</i> , 2009, 62, 105-108.	2.4	346
30	A family history of fracture and fracture risk: a meta-analysis. <i>Bone</i> , 2004, 35, 1029-1037.	2.9	344
31	Development and use of FRAX® in osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 407-413.	3.1	320
32	A systematic review of intervention thresholds based on FRAX. <i>Archives of Osteoporosis</i> , 2016, 11, 25.	2.4	317
33	FRAX underestimates fracture risk in patients with diabetes. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 301-308.	2.8	307
34	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. <i>Calcified Tissue International</i> , 2019, 105, 1-14.	3.1	295
35	A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 317-325.	2.5	292
36	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2257-2276.	3.1	291

#	ARTICLE	IF	CITATIONS
37	Imminent risk of fracture after fracture. <i>Osteoporosis International</i> , 2017, 28, 775-780.	3.1	275
38	The Incidence of Vertebral Fractures in Men and Women: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1051-1056.	2.8	265
39	Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. <i>Maturitas</i> , 2013, 75, 392-396.	2.4	264
40	Guidance for the adjustment of FRAX according to the dose of glucocorticoids. <i>Osteoporosis International</i> , 2011, 22, 809-816.	3.1	248
41	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1700-1707.	2.8	247
42	A high incidence of vertebral fracture in women with breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 1179-1181.	6.4	243
43	Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. <i>Breast Cancer Research</i> , 2006, 8, R13.	5.0	243
44	Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2350-2358.	2.8	243
45	Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1591-1600.	2.8	241
46	WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. <i>PLoS Genetics</i> , 2012, 8, e1002745.	3.5	240
47	A primary care cross-sectional study of undiagnosed adult coeliac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 407-413.	1.6	237
48	Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. <i>Nature Reviews Endocrinology</i> , 2020, 16, 437-447.	9.6	237
49	Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. <i>PLoS Genetics</i> , 2011, 7, e1001372.	3.5	233
50	SCOPE 2021: a new scorecard for osteoporosis in Europe. <i>Archives of Osteoporosis</i> , 2021, 16, 82.	2.4	233
51	Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1254-1260.	2.8	220
52	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. <i>Osteoporosis International</i> , 2020, 31, 1-12.	3.1	220
53	Clodronate decreases the frequency of skeletal metastases in women with breast cancer. <i>Bone</i> , 1996, 19, 663-667.	2.9	218
54	Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 852-860.	3.6	216

#	ARTICLE	IF	CITATIONS
55	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008, 34, S3-S18.	7.7	209
56	Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 741-747.	13.7	206
57	Risk of vertebral fracture in women with rheumatoid arthritis.. <i>BMJ: British Medical Journal</i> , 1993, 306, 558-558.	2.3	204
58	Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 135-141.	2.8	180
59	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	7.4	180
60	Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 117-121.	0.9	176
61	FRAX [®] with and without Bone Mineral Density. <i>Calcified Tissue International</i> , 2012, 90, 1-13.	3.1	173
62	Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. <i>European Journal of Haematology</i> , 1992, 49, 192-198.	2.2	172
63	Bisphosphonates in oncology. <i>Bone</i> , 2011, 49, 71-76.	2.9	167
64	Duration of response with oral clodronate in Paget's disease of bone. <i>Bone</i> , 1996, 18, 185-190.	2.9	160
65	Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 1035-1043.	2.5	160
66	Risk Factors for Incident Vertebral Fractures in Men and Women: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1172-1180.	2.8	160
67	Fracture prediction and calibration of a Canadian FRAX [®] tool: a population-based report from CaMos. <i>Osteoporosis International</i> , 2011, 22, 829-837.	3.1	160
68	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. <i>Osteoporosis International</i> , 2017, 28, 1507-1529.	3.1	160
69	Oral Clodronate and Reduction in Loss of Bone Mineral Density in Women With Operable Primary Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1998, 90, 704-708.	6.3	159
70	Adjusting Fracture Probability by Trabecular Bone Score. <i>Calcified Tissue International</i> , 2015, 96, 500-509.	3.1	155
71	Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. <i>Bone</i> , 2009, 45, 1053-1058.	2.9	149
72	Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX [®] . <i>Bone</i> , 2009, 44, 1049-1054.	2.9	147

#	ARTICLE	IF	CITATIONS
73	UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 2022, 17, 58.	2.4	146
74	Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporosis International, 2011, 22, 817-827.	3.1	144
75	A brief history of FRAX. Archives of Osteoporosis, 2018, 13, 118.	2.4	144
76	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. Calcified Tissue International, 2014, 94, 560-567.	3.1	141
77	Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporosis International, 2009, 20, 811-817.	3.1	134
78	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.6	132
79	Spine—hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporosis International, 2011, 22, 839-847.	3.1	131
80	Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis. Journal of Bone and Mineral Research, 2004, 19, 906-913.	2.8	130
81	From relative risk to absolute fracture risk calculation: The FRAX algorithm. Current Osteoporosis Reports, 2009, 7, 77-83.	3.6	130
82	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Human Molecular Genetics, 2014, 23, 1923-1933.	2.9	130
83	Vertebral Deformities in Rheumatoid Arthritis. Archives of Internal Medicine, 2004, 164, 420.	3.8	129
84	Protective effect of β^2 blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 2007, 40, 1209-1216.	2.9	129
85	Epidemiology of vertebral osteoporosis. Bone, 1992, 13, S1-S10.	2.9	126
86	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Journal of Bone and Mineral Research, 2012, 27, 1480-1486.	2.8	126
87	Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 2016, 27, 21-31.	3.1	126
88	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.1	126
89	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.4	125
90	Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, 2007, 11, iii-iv, ix-xi, 1-231.	2.8	124

#	ARTICLE	IF	CITATIONS
91	A meta-analysis of milk intake and fracture risk: low utility for case finding. <i>Osteoporosis International</i> , 2005, 16, 799-804.	3.1	123
92	The Osteoporosis Treatment Gap. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1926-1928.	2.8	122
93	Characteristics of recurrent fractures. <i>Osteoporosis International</i> , 2018, 29, 1747-1757.	3.1	122
94	BMD, clinical risk factors and their combination for hip fracture prevention. <i>Osteoporosis International</i> , 2009, 20, 1675-1682.	3.1	121
95	Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The chingford study. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 817-822.	2.8	121
96	The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. <i>Journal of Rheumatology</i> , 1999, 26, 842-8.	2.0	119
97	Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 728-736.	2.8	114
98	The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)â€™quality of life during the first 4Âmonths after fracture. <i>Osteoporosis International</i> , 2013, 24, 811-823.	3.1	114
99	Assessment of broadband ultrasound attenuation in the os calcis <i>in vitro</i>. <i>Clinical Science</i> , 1990, 78, 221-225.	4.3	109
100	Assessment of fracture risk. <i>European Journal of Radiology</i> , 2009, 71, 392-397.	2.6	109
101	Broadband ultrasound attenuation in the os calcis: relationship to bone mineral at other skeletal sites. <i>Clinical Science</i> , 1990, 78, 227-233.	4.3	108
102	Abdominal Aortic Calcification Detected on Lateral Spine Images From a Bone Densitometer Predicts Incident Myocardial Infarction or Stroke in Older Women. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 409-416.	2.8	108
103	Does osteoporosis therapy invalidate FRAX for fracture prediction?. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1243-1251.	2.8	105
104	Assessing the Impact of Osteoporosis on the Burden of Hip Fractures. <i>Calcified Tissue International</i> , 2013, 92, 42-49.	3.1	104
105	Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1923-1930.	2.8	104
106	Fracture risk assessment without bone density measurement in routine clinical practice. <i>Osteoporosis International</i> , 2012, 23, 75-85.	3.1	102
107	Lumbar spine texture enhances 10-year fracture probability assessment. <i>Osteoporosis International</i> , 2014, 25, 2271-2277.	3.1	101
108	Intervention Thresholds and the Diagnosis of Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1747-1753.	2.8	100

#	ARTICLE	IF	CITATIONS
109	Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2012, 23, 423-431.	3.1	95
110	Worldwide uptake of FRAX. <i>Archives of Osteoporosis</i> , 2014, 9, 166.	2.4	95
111	A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®. <i>Bone</i> , 2010, 47, 729-735.	2.9	93
112	Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4489-4496.	3.6	92
113	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 47-58.	2.9	91
114	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. <i>Human Molecular Genetics</i> , 2014, 23, 3054-3068.	2.9	90
115	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. <i>European Geriatric Medicine</i> , 2016, 7, 243-246.	2.8	90
116	Prevalence and Causes of Low Bone Density and Fractures in Kidney Transplant Patients*. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1863-1870.	2.8	89
117	Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1561-1568.	2.8	89
118	The effects of a FRAX® revision for the USA. <i>Osteoporosis International</i> , 2010, 21, 35-40.	3.1	89
119	High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. <i>Osteoporosis International</i> , 2012, 23, 391-397.	3.1	89
120	Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS. <i>Osteoporosis International</i> , 2018, 29, 557-566.	3.1	88
121	Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. <i>European Journal of Cancer</i> , 2007, 43, 2523-2531.	2.8	85
122	Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. <i>Journal of Clinical Densitometry</i> , 2011, 14, 212-219.	1.2	85
123	Treatment of osteoporosis in men. <i>Bone</i> , 2013, 53, 134-144.	2.9	84
124	A decade of FRAX: how has it changed the management of osteoporosis?. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 187-196.	2.9	83
125	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. <i>Journal of Clinical Densitometry</i> , 2011, 14, 171-180.	1.2	82
126	A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. <i>Osteoporosis International</i> , 2011, 22, 2347-2355.	3.1	82

#	ARTICLE	IF	CITATIONS
127	Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. <i>Diabetes Care</i> , 2020, 43, 137-144.	8.6	82
128	FRAX Update. <i>Journal of Clinical Densitometry</i> , 2017, 20, 360-367.	1.2	81
129	Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2150-2157.	2.8	81
130	Effects of third-generation aromatase inhibitors on bone. <i>European Journal of Cancer</i> , 2006, 42, 1044-1051.	2.8	78
131	Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1014-1021.	2.8	78
132	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. <i>British Journal of Cancer</i> , 1993, 67, 560-563.	6.4	77
133	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. <i>Osteoporosis International</i> , 2020, 31, 2271-2286.	3.1	76
134	The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. <i>Osteoporosis International</i> , 2021, 32, 251-259.	3.1	75
135	Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2511-2519.	2.8	74
136	Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. <i>Osteoporosis International</i> , 2015, 26, 1979-1987.	3.1	74
137	Epidemiology of fracture in the Russian Federation and the development of a FRAX model. <i>Archives of Osteoporosis</i> , 2012, 7, 67-73.	2.4	73
138	Osteoporosis and fractures in women: the burden of disease. <i>Climacteric</i> , 2022, 25, 4-10.	2.4	71
139	Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 483-491.	2.8	69
140	Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3-Year Randomized Placebo-Controlled Clinical Trial With a 2-Year Open Extension. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1057-1064.	2.8	69
141	Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. <i>Archives of Osteoporosis</i> , 2011, 6, 179-188.	2.4	69
142	Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. <i>Clinical Cancer Research</i> , 2007, 13, 5406-5410.	7.0	68
143	HIV and bone disease. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 66-77.	3.0	68
144	A precise method for the assessment of tibial ultrasound velocity. <i>Osteoporosis International</i> , 1996, 6, 1-7.	3.1	66

#	ARTICLE	IF	CITATIONS
145	Incidence of hip fracture in Brazil and the development of a FRAX model. Archives of Osteoporosis, 2015, 10, 224.	2.4	66
146	Osteoporosis in Europe: a compendium of country-specific reports. Archives of Osteoporosis, 2022, 17, 23.	2.4	66
147	Effects of intravenous etidronate disodium on skeletal and calcium metabolism. American Journal of Medicine, 1987, 82, 55-70.	1.5	64
148	Serum Retinoids and \hat{I}^2 -Carotene as Predictors of Hip and Other Fractures in Elderly Women. Journal of Bone and Mineral Research, 2005, 20, 913-920.	2.8	64
149	Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference. Clinical Cancer Research, 2008, 14, 6387-6395.	7.0	64
150	Bone turnover and biochemical markers in malignancy. Cancer, 1997, 80, 1538-1545.	4.1	63
151	Overview of Fracture Prediction Tools. Journal of Clinical Densitometry, 2017, 20, 444-450.	1.2	62
152	Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 2008, 14, 6-12.	1.6	61
153	Use of DXA-Based Structural Engineering Models of the Proximal Femur to Discriminate Hip Fracture. Journal of Bone and Mineral Research, 2009, 24, 33-42.	2.8	61
154	Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 2014, 25, 2533-2543.	3.1	61
155	Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2018, 33, 510-516.	2.8	61
156	The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treatment Reviews, 2005, 31, 115-142.	7.7	60
157	Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporosis International, 2014, 25, 251-263.	3.1	60
158	Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporosis International, 2014, 25, 235-241.	3.1	60
159	Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. JAMA Psychiatry, 2017, 74, 641.	11.0	60
160	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
161	Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.. Journal of Clinical Oncology, 1995, 13, 929-934.	1.6	59
162	FRAX and fracture prediction without bone mineral density. Climacteric, 2015, 18, 2-9.	2.4	58

#	ARTICLE	IF	CITATIONS
163	The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 845-851.	2.8	58
164	Evaluation of the risk of hip fracture. <i>Bone</i> , 1996, 18, S127-S132.	2.9	57
165	Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. <i>Osteoporosis International</i> , 2012, 23, 991-999.	3.1	57
166	FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. <i>Osteoporosis International</i> , 2015, 26, 2091-2099.	3.1	56
167	Risk factors in osteoporosis. <i>Maturitas</i> , 1998, 30, 229-233.	2.4	54
168	A FRAX® model for the assessment of fracture probability in Belgium. <i>Osteoporosis International</i> , 2011, 22, 453-461.	3.1	53
169	Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. <i>Osteoporosis International</i> , 2020, 31, 1817-1828.	3.1	53
170	Use of clinical risk factors to identify postmenopausal women with vertebral fractures. <i>Osteoporosis International</i> , 2007, 18, 35-43.	3.1	52
171	Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts. <i>Calcified Tissue International</i> , 2014, 95, 428-435.	3.1	52
172	Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1568-1574.	2.8	52
173	Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1428-1435.	2.8	52
174	Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. <i>Osteoporosis International</i> , 2020, 31, 1059-1067.	3.1	52
175	A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. <i>Osteoporosis International</i> , 2012, 23, 2507-2515.	3.1	51
176	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. <i>Calcified Tissue International</i> , 2019, 105, 109-124.	3.1	51
177	Effect of calcitonin on vertebral and other fractures. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1999, 92, 143-150.	0.5	50
178	Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. <i>Osteoporosis International</i> , 2011, 22, 2359-2364.	3.1	49
179	High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1390-1396.	2.8	49
180	Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. <i>Osteoporosis International</i> , 2014, 25, 2729-2741.	3.1	49

#	ARTICLE	IF	CITATIONS
181	Hip Axis Length Is a FRAX- and Bone Density-Independent Risk Factor for Hip Fracture in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2063-2070.	3.6	48
182	Rationale for the use of bisphosphonates in bone metastases. <i>Bone</i> , 1991, 12, S13-S18.	2.9	47
183	Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. <i>Bone</i> , 2001, 28, 310-315.	2.9	47
184	“Sink or swim”™: an evaluation of the clinical characteristics of individuals with high bone mass. <i>Osteoporosis International</i> , 2012, 23, 643-654.	3.1	47
185	A comparison of case-finding strategies in the UK for the management of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 907-915.	3.1	47
186	Paget's disease of bone and unvaccinated dogs. <i>Bone</i> , 1996, 19, 47-50.	2.9	46
187	Bisphosphonates in multiple myeloma. <i>Cancer</i> , 2000, 88, 3022-3032.	4.1	46
188	The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®. <i>Osteoporosis International</i> , 2010, 21, 495-505.	3.1	46
189	Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. <i>Journal of Clinical Densitometry</i> , 2016, 19, 326-331.	1.2	46
190	Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. <i>Drug Safety</i> , 2003, 26, 661-671.	3.2	45
191	Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1020-1026.	2.8	45
192	Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. <i>PLoS Medicine</i> , 2020, 17, e1003152.	8.4	45
193	Alendronate in the treatment of Paget's disease of bone. <i>Bone</i> , 1997, 20, 263-271.	2.9	44
194	Fracture risk assessment. <i>Clinical Biochemistry</i> , 2012, 45, 887-893.	1.9	44
195	The Effect of Latitude on the Risk and Seasonal Variation in Hip Fracture in Sweden. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2217-2223.	2.8	44
196	FRAX updates 2012. <i>Current Opinion in Rheumatology</i> , 2012, 24, 554-560.	4.3	43
197	FRAX- vs. T-score-based intervention thresholds for osteoporosis. <i>Osteoporosis International</i> , 2017, 28, 3099-3105.	3.1	42
198	Osteoporotic fractures: An unusual presentation of haemochromatosis. <i>Bone</i> , 1992, 13, 431-433.	2.9	41

#	ARTICLE	IF	CITATIONS
199	Official Positions for FRAX® Clinical Regarding Biochemical Markers. <i>Journal of Clinical Densitometry</i> , 2011, 14, 220-222.	1.2	41
200	FRAX predicts incident falls in elderly men: findings from MrOs Sweden. <i>Osteoporosis International</i> , 2016, 27, 267-274.	3.1	41
201	In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. <i>Bone</i> , 2018, 113, 161-168.	2.9	41
202	Economic impact of using clodronate in the management of patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999, 104, 358-364.	2.5	40
203	Effects of antiresorptive treatment on nonvertebral fracture outcomes. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2411-2418.	2.8	40
204	Can we improve the prediction of hip fracture by assessing bone structure using shape and appearance modelling?. <i>Bone</i> , 2013, 53, 188-193.	2.9	40
205	The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1625-1631.	2.8	40
206	Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. <i>Osteoporosis International</i> , 2018, 29, 1407-1417.	3.1	40
207	Intra-Individual Variation in Fasting Urinary Calcium- and Hydroxyproline-Creatinine Ratios Measured in Metabolic Bone Clinic Patients as Both Outpatients and Inpatients. <i>Annals of Clinical Biochemistry</i> , 1994, 31, 272-276.	1.6	39
208	Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. <i>Maturitas</i> , 2000, 37, 75-81.	2.4	39
209	Approaches to the targeting of treatment for osteoporosis. <i>Nature Reviews Rheumatology</i> , 2009, 5, 425-431.	8.0	39
210	Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model. <i>Calcified Tissue International</i> , 2013, 92, 429-436.	3.1	38
211	Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 640-649.	2.8	38
212	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019, 30, 1733-1743.	3.1	38
213	An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. <i>Osteoporosis International</i> , 2021, 32, 1951-1960.	3.1	38
214	Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. <i>European Journal of Cancer</i> , 2010, 46, 558-565.	2.8	37
215	FRAX updates 2016. <i>Current Opinion in Rheumatology</i> , 2016, 28, 433-441.	4.3	37
216	Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. <i>Osteoporosis International</i> , 2018, 29, 751-758.	3.1	37

#	ARTICLE	IF	CITATIONS
217	The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma. <i>Drugs</i> , 2001, 61, 1253-1274.	10.9	36
218	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. <i>Calcified Tissue International</i> , 2001, 68, 348-351.	3.1	36
219	The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures—An open label study. <i>Bone</i> , 2005, 36, 47-51.	2.9	36
220	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. <i>Quality of Life Research</i> , 2018, 27, 707-716.	3.1	36
221	An appendix to the 2012 IOF—ECTS guidelines for the management of glucocorticoid-induced osteoporosis. <i>Archives of Osteoporosis</i> , 2012, 7, 25-30.	2.4	35
222	FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. <i>Osteoporosis International</i> , 2015, 26, 2677-2684.	3.1	35
223	Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2487-2506.	3.6	35
224	Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. <i>Genome Medicine</i> , 2021, 13, 16.	8.2	35
225	Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. <i>Osteoporosis International</i> , 2009, 20, 2055-2061.	3.1	34
226	FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. <i>Bone</i> , 2010, 47, 430-437.	2.9	34
227	Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. <i>Osteoporosis International</i> , 2015, 26, 2347-2353.	3.1	34
228	Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. <i>Osteoporosis International</i> , 2006, 17, 535-542.	3.1	33
229	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019, 127, 401-418.	2.9	33
230	Sarcopenia Definitions as Predictors of Fracture Risk Independent of FRAX®, Falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1235-1244.	2.8	33
231	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. <i>Osteoporosis International</i> , 2022, 33, 2103-2136.	3.1	33
232	Diphosphonates and phosphate homeostasis in man. <i>Clinical Science</i> , 1988, 74, 607-612.	4.3	32
233	Sustained response to intravenous alendronate in postmenopausal osteoporosis. <i>Bone</i> , 1995, 17, 517-520.	2.9	32
234	Genome-wide association study for radiographic vertebral fractures: A potential role for the 16q24 BMD locus. <i>Bone</i> , 2014, 59, 20-27.	2.9	32

#	ARTICLE	IF	CITATIONS
235	Is the Swedish FRAX model appropriate for Swedish immigrants?. <i>Osteoporosis International</i> , 2015, 26, 2617-2622.	3.1	32
236	SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. <i>Calcified Tissue International</i> , 2016, 98, 417-425.	3.1	32
237	Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. <i>Osteoporosis International</i> , 2011, 22, 1411-1418.	3.1	31
238	The distribution of FRAX®-based probabilities in women from Japan. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 700-705.	2.7	31
239	The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1. <i>Progress in Basic and Clinical Pharmacology</i> , 1990, 4, 89-136.	0.1	30
240	Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). <i>British Journal of Cancer</i> , 1994, 69, 914-917.	6.4	30
241	Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. <i>Archives of Osteoporosis</i> , 2012, 7, 237-246.	2.4	30
242	A comparison of the acute effects of subcutaneous and intranasal calcitonin. <i>Clinical Science</i> , 1990, 78, 215-219.	4.3	29
243	Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. <i>Bone</i> , 1991, 12, 17-20.	2.9	29
244	Analysis of Body Composition in Individuals With High Bone Mass Reveals a Marked Increase in Fat Mass in Women But Not Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 818-828.	3.6	29
245	A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3Åyears. <i>Rheumatology International</i> , 2013, 33, 2231-2239.	3.0	29
246	The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. <i>Osteoporosis International</i> , 2014, 25, 2445-2451.	3.1	29
247	Case-Finding for Adult Celiac Disease in Patients with Reduced Bone Mineral Density. <i>Digestive Diseases and Sciences</i> , 2005, 50, 587-592.	2.3	28
248	Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. <i>Osteoporosis International</i> , 2011, 22, 955-965.	3.1	28
249	The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. <i>Archives of Osteoporosis</i> , 2012, 7, 229-235.	2.4	28
250	FRAX provides robust fracture prediction regardless of socioeconomic status. <i>Osteoporosis International</i> , 2014, 25, 61-69.	3.1	28
251	The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. <i>Osteoporosis International</i> , 2021, 32, 75-84.	3.1	28
252	Treatment of skeletal disease in breast cancer with clodronate. <i>Bone</i> , 1991, 12, S25-S30.	2.9	27

#	ARTICLE	IF	CITATIONS
253	Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate). Drug Safety, 1992, 7, 162-165.	3.2	27
254	The effects of intravenous alendronate in Paget's disease of bone. Journal of Bone and Mineral Research, 1995, 10, 1094-1100.	2.8	27
255	Screening for chronic comorbid diseases in people with <sc>HIV</sc>: the need for a strategic approach. HIV Medicine, 2013, 14, 1-11.	2.2	27
256	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 2013, 28, 1007-1013.	2.8	27
257	Can Change in FRAX Score Be Used to "Treat to Target"? A Population-Based Cohort Study. Journal of Bone and Mineral Research, 2014, 29, 1074-1080.	2.8	27
258	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 2020, 25, 100311.	2.4	27
259	Rationale for the use of clodronate in osteoporosis. Osteoporosis International, 1993, 3, 23-28.	3.1	26
260	Metacarpal Morphometry Using a Semi-automated Technique in the Assessment of Osteoporosis and Vertebral Fracture Risk. Osteoporosis International, 2000, 11, 953-958.	3.1	26
261	Comparison of three intravenous regimens of clodronate in paget disease of bone. Journal of Bone and Mineral Research, 1996, 11, 178-182.	2.8	26
262	Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporosis International, 2019, 30, 917-922.	3.1	26
263	Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporosis International, 2021, 32, 39-46.	3.1	26
264	Short-term Reproducibility of Proximal Femur Bone Mineral Density in the Elderly. Calcified Tissue International, 1998, 63, 296-299.	3.1	25
265	The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone, 2016, 92, 94-99.	2.9	25
266	Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporosis International, 2020, 31, 67-75.	3.1	25
267	Deep Learning With Electronic Health Records for Short-Term Fracture Risk Identification: Crystal Bone Algorithm Development and Validation. Journal of Medical Internet Research, 2020, 22, e22550.	4.3	25
268	Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women. Archives of Osteoporosis, 2013, 8, 145.	2.4	24
269	Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate. Archives of Osteoporosis, 2017, 12, 98.	2.4	24
270	Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporosis International, 2019, 30, 2195-2203.	3.1	24

#	ARTICLE	IF	CITATIONS
271	The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. <i>Osteoporosis International</i> , 2021, 32, 1547-1555.	3.1	24
272	Medical Management of Hypercalcemia. <i>Calcified Tissue International</i> , 2003, 74, 1-11.	3.1	23
273	How to decide who to treat. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 711-726.	3.3	23
274	The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 339-349.	3.1	23
275	Bisphosphonates in osteoporosis: NICE and easy?. <i>Lancet, The</i> , 2017, 390, 2243-2244.	13.7	23
276	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	2.9	22
277	Effects of Clodronate in Severe Hyperparathyroid Bone Disease in Chronic Renal Failure. <i>Nephron</i> , 1990, 56, 6-12.	1.8	21
278	Evaluation of FRAX to characterise fracture risk in Poland. <i>Osteoporosis International</i> , 2011, 22, 2507-2512.	3.1	21
279	Epidemiology of osteoporotic fracture in Kazakhstan and development of a country specific FRAX model. <i>Archives of Osteoporosis</i> , 2020, 15, 30.	2.4	21
280	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1014-1021.	2.8	21
281	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. <i>Osteoporosis International</i> , 2021, 32, 817-829.	3.1	21
282	The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. <i>Osteoporosis International</i> , 2021, 32, 47-54.	3.1	21
283	Pseudohyperphosphataemia in multiple myeloma.. <i>BMJ: British Medical Journal</i> , 1989, 299, 1381-1382.	2.3	20
284	The Use of Bone Markers in a 6-Week Study to Assess the Efficacy of Oral Clodronate in Patients with Metastatic Bone Disease. <i>Calcified Tissue International</i> , 2007, 81, 341-351.	3.1	20
285	Epidemiological Burden of Postmenopausal Osteoporosis in Italy from 2010 to 2020: Estimations from a Disease Model. <i>Calcified Tissue International</i> , 2014, 95, 419-427.	3.1	20
286	Fracture risk assessment by the FRAX model. <i>Climacteric</i> , 2022, 25, 22-28.	2.4	20
287	Epidemiology of osteoporotic fracture in Moldova and development of a country-specific FRAX model. <i>Archives of Osteoporosis</i> , 2020, 15, 13.	2.4	20
288	The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture. <i>Medical Decision Making</i> , 2009, 29, 678-689.	2.4	19

#	ARTICLE	IF	CITATIONS
289	Consensus of Official Position of IOF/ISCD FRAX Initiatives in Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2014, 17, 150-155.	1.2	19
290	FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry. <i>Osteoporosis International</i> , 2017, 28, 2557-2564.	3.1	19
291	Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1302-1309.	3.6	19
292	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. <i>Archives of Osteoporosis</i> , 2010, 5, 19-48.	2.4	18
293	Selection of Women Aged 50-64 Yr for Bone Density Measurement. <i>Journal of Clinical Densitometry</i> , 2013, 16, 570-578.	1.2	18
294	Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. <i>Osteoporosis International</i> , 2018, 29, 1367-1378.	3.1	18
295	Validation of calcaneus trabecular microstructure measurements by HR-pQCT. <i>Bone</i> , 2018, 106, 69-77.	2.9	18
296	FRAX® based intervention thresholds for management of osteoporosis in Singaporean women. <i>Archives of Osteoporosis</i> , 2018, 13, 130.	2.4	18
297	Estimating an Individual's Probability of Revision Surgery After Knee Replacement: A Comparison of Modeling Approaches Using a National Data Set. <i>American Journal of Epidemiology</i> , 2018, 187, 2252-2262.	3.4	18
298	Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). <i>Osteoporosis International</i> , 2018, 29, 1511-1513.	3.1	18
299	Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. <i>Osteoporosis International</i> , 2021, 32, 113-122.	3.1	18
300	Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). <i>Journal of Bone and Mineral Research</i> , 2020, 36, 654-661.	2.8	18
301	Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. <i>Bone</i> , 1987, 8 Suppl 1, S35-41.	2.9	18
302	Lateral back pain identifies prevalent vertebral fractures in post-menopausal women: cross-sectional analysis of a primary care-based cohort. <i>Rheumatology</i> , 2010, 49, 505-512.	1.9	17
303	Development and validation of a disease model for postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 771-780.	3.1	17
304	A comparative study of using non-hip bone density inputs with FRAX®. <i>Osteoporosis International</i> , 2012, 23, 853-860.	3.1	17
305	Appendicular lean mass and fracture risk assessment: implications for FRAX® and sarcopenia. <i>Osteoporosis International</i> , 2019, 30, 537-539.	3.1	17
306	Loss in DXA-estimated total body lean mass but not fat mass predicts incident major osteoporotic fracture and hip fracture independently from FRAX: a registry-based cohort study. <i>Archives of Osteoporosis</i> , 2020, 15, 96.	2.4	17

#	ARTICLE	IF	CITATIONS
307	Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. <i>Osteoporosis International</i> , 2020, 31, 1499-1506.	3.1	17
308	Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. <i>Bone</i> , 2014, 59, 20-7.	2.9	17
309	Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. <i>JAMA Network Open</i> , 2022, 5, e2215396.	5.9	17
310	Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment. <i>Drug Investigation</i> , 1994, 7, 26-33.	0.6	16
311	Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. <i>Archives of Osteoporosis</i> , 2012, 7, 209-218.	2.4	16
312	CORRIGENDA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3219-3219.	3.6	16
313	Establishing and evaluating FRAX [®] probability thresholds in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 161-168.	1.7	16
314	Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. <i>Archives of Osteoporosis</i> , 2018, 13, 42.	2.4	16
315	Bone turnover and biochemical markers in malignancy. <i>Cancer</i> , 1997, 80, 1538-1545.	4.1	16
316	Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study. <i>Osteoporosis International</i> , 2020, 31, 1079-1087.	3.1	16
317	Assessment of osteopenia from spine radiographs using two different methods: the Chingford study. <i>British Journal of Radiology</i> , 1996, 69, 451-456.	2.2	15
318	Clodronate. <i>Cancer</i> , 1997, 80, 1691-1695.	4.1	15
319	Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. <i>Bone</i> , 2000, 26, 525-528.	2.9	15
320	Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. <i>Current Medical Research and Opinion</i> , 2005, 21, 805-815.	1.9	15
321	Evaluation of the FRAX Model for Hip Fracture Predictions in the Population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE). <i>Calcified Tissue International</i> , 2014, 95, 39-45.	3.1	15
322	Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. <i>Osteoporosis International</i> , 2014, 25, 1831-1836.	3.1	15
323	Direct comparison of FRAXR and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. <i>Osteoporosis International</i> , 2016, 27, 2689-2695.	3.1	15
324	A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. <i>Osteoporosis International</i> , 2016, 27, 417-419.	3.1	15

#	ARTICLE	IF	CITATIONS
325	Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK – an analysis of anonymous website activity. <i>Osteoporosis International</i> , 2017, 28, 71-76.	3.1	15
326	Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. <i>Osteoporosis International</i> , 2018, 29, 759-767.	3.1	15
327	Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. <i>Osteoporosis International</i> , 2019, 30, 1745-1754.	3.1	15
328	Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. <i>Osteoporosis International</i> , 2021, 32, 1601-1608.	3.1	15
329	Clodronate and osteoporosis. <i>Maturitas</i> , 1996, 23, S81-S86.	2.4	14
330	The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review. <i>Bone</i> , 2017, 99, 39-46.	2.9	14
331	The effect of bisphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. <i>Bone</i> , 2020, 131, 115158.	2.9	14
332	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. <i>Bone Reports</i> , 2020, 13, 100729.	0.4	14
333	Use of age-dependent FRAX-based intervention thresholds for Singapore. <i>Archives of Osteoporosis</i> , 2020, 15, 104.	2.4	14
334	Short time horizons for fracture prediction tools: time for a rethink. <i>Osteoporosis International</i> , 2021, 32, 1019-1025.	3.1	14
335	Treatment of osteoporosis with vitamin D. <i>Osteoporosis International</i> , 1997, 7, 140-146.	3.1	13
336	Clinical Assessment of Bone Mass, Quality and Architecture. <i>Osteoporosis International</i> , 1999, 9, S24-S28.	3.1	13
337	Goal-directed therapy in osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 439-441.	2.8	13
338	Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. <i>Archives of Osteoporosis</i> , 2019, 14, 93.	2.4	13
339	Clodronate. <i>Bone</i> , 2021, 143, 115715.	2.9	13
340	Individuals with high bone mass have increased progression of radiographic and clinical features of knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 1180-1190.	1.3	13
341	Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. <i>Osteoporosis International</i> , 2022, 33, 1725-1738.	3.1	13
342	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. <i>Archives of Osteoporosis</i> , 2022, 17, .	2.4	13

#	ARTICLE	IF	CITATIONS
343	TRANSIENT TASTE-LOSS DURING TREATMENT WITH ETIDRONATE. <i>Lancet, The</i> , 1987, 330, 637.	13.7	12
344	Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface. <i>Clinical Science</i> , 1991, 81, 543-549.	0.0	12
345	Distinction between Focally Accelerated Bone Formation and Osteomalacia in Carcinoma of Prostate Metastasised to Bone. <i>British Journal of Urology</i> , 1993, 72, 98-103.	0.1	12
346	Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 74-78.	2.8	12
347	Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients. <i>Journal of International Medical Research</i> , 2008, 36, 400-413.	1.0	12
348	Comparison of HR-pQCT- and microCT-based finite element models for the estimation of the mechanical properties of the calcaneus trabecular bone. <i>Biomechanics and Modeling in Mechanobiology</i> , 2018, 17, 1715-1730.	2.8	12
349	JointCalc: A web-based personalised patient decision support tool for joint replacement. <i>International Journal of Medical Informatics</i> , 2020, 142, 104217.	3.3	12
350	FRAX and ethnicity. <i>Osteoporosis International</i> , 2020, 31, 2063-2067.	3.1	12
351	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1861-1872.	1.9	12
352	Epidemiology of hip fracture in Botswana. <i>Archives of Osteoporosis</i> , 2021, 16, 24.	2.4	12
353	Treatment of the hypercalcaemia of malignancy with intravenous clodronate. <i>Bone</i> , 1987, 8 Suppl 1, S43-51.	2.9	12
354	Neurological Complications of Paget's Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 135-144.	0.8	11
355	Shape, Structural Properties, and Cortical Stability Along the Femoral Neck: A Study Using Clinical QCT. <i>Journal of Clinical Densitometry</i> , 2008, 11, 373-382.	1.2	11
356	FRAX® Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011, 14, 181-183.	1.2	11
357	FRAX-based intervention and assessment thresholds for osteoporosis in Romania. <i>Archives of Osteoporosis</i> , 2013, 8, 164.	2.4	11
358	Magnitude of fragility fracture risk in the very old—are we meeting their needs? The Newcastle 85+ Study. <i>Osteoporosis International</i> , 2015, 26, 123-130.	3.1	11
359	Low risk for hip fracture and high risk for hip arthroplasty due to osteoarthritis among Swedish farmers. <i>Osteoporosis International</i> , 2018, 29, 741-749.	3.1	11
360	Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study. <i>Bone</i> , 2018, 110, 386-391.	2.9	11

#	ARTICLE	IF	CITATIONS
361	Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Archives of Osteoporosis, 2019, 14, 15.	2.4	11
362	Fracture risk assessment in celiac disease: a registry-based cohort study. Osteoporosis International, 2021, 32, 93-99.	3.1	11
363	Femoral neck strain prediction during level walking using a combined musculoskeletal and finite element model approach. PLoS ONE, 2021, 16, e0245121.	2.5	11
364	FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 2021, 16, 87.	2.4	11
365	MRI-based anatomical characterisation of lower-limb muscles in older women. PLoS ONE, 2020, 15, e0242973.	2.5	11
366	Use of diphosphonates in hypercalcaemia due to malignancy. Lancet, The, 1990, 335, 170-1.	13.7	11
367	Clodronate in the medical management of hyperparathyroidism. Bone, 1987, 8 Suppl 1, S69-77.	2.9	11
368	Letters. Osteoporosis International, 1994, 4, 117-119.	3.1	10
369	Tumour induced hypercalcaemia: A case for active treatment. Clinical Oncology, 1994, 6, 172-176.	1.4	10
370	The US FRAX® filter: avoiding confusion or hindering progress?. Osteoporosis International, 2010, 21, 885-885.	3.1	10
371	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. Oncologist, 2019, 24, 1432-1438.	3.7	10
372	Temporal changes in access to FRAX® in Thailand between 2010 and 2018. Archives of Osteoporosis, 2019, 14, 66.	2.4	10
373	FRAX-based fracture probabilities in South Africa. Archives of Osteoporosis, 2021, 16, 51.	2.4	10
374	Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). Osteoporosis International, 2022, 33, 57-66.	3.1	10
375	Vertebral osteophytosis and vertebral deformities in an elderly population sample. Wiener Klinische Wochenschrift, 2000, 112, 407-12.	1.9	10
376	Epidemiology of Hip Fractures in Two Regions of Ukraine. Journal of Osteoporosis, 2018, 2018, 1-6.	0.5	9
377	Increased development of radiographic hip osteoarthritis in individuals with high bone mass: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 4.	3.5	9
378	EPIDEMIOLOGY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN FEDERATION AND THE RUSSIAN MODEL OF FRAX. Osteoporosis and Bone Diseases, 2014, 17, 3-8.	1.4	9

#	ARTICLE	IF	CITATIONS
379	The Effect of Fracture Recency on Observed 10-Year Fracture Probability: A Registry-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 848-855.	2.8	9
380	Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials. <i>Osteoporosis International</i> , 2022, 33, 2297-2305.	3.1	9
381	Between Isolation and Intrusion: The Patient Self-Determination Act. <i>Journal of Law, Medicine, and Ethics</i> , 1991, 19, 80-82.	0.6	8
382	CONSEQUENCES OF NEOPLASIA INDUCED BONE-RESORPTION AND THE USE OF CLODRONATE (REVIEW). <i>International Journal of Oncology</i> , 1994, 5, 713-31.	3.3	8
383	Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg. <i>Current Medical Research and Opinion</i> , 2009, 25, 2951-2960.	1.9	8
384	Unilateral compressive optic neuropathy due to skull hyperostosis secondary to nutritional vitamin A deficiency. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 75-7.	1.0	8
385	One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. <i>Osteoporosis International</i> , 2022, 33, 185-194.	3.1	8
386	The effect of alendronate on renal tubular reabsorption of phosphate. <i>Bone and Mineral</i> , 1994, 27, 51-56.	1.9	7
387	Is a Calculated Total Hip BMD of Clinical Use?. <i>Osteoporosis International</i> , 2000, 11, 368-371.	3.1	7
388	Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density. <i>Postgraduate Medical Journal</i> , 2003, 79, 581-584.	1.8	7
389	Total Hip Bone Area Affects Fracture Prediction With FRAX® in Canadian White Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4242-4249.	3.6	7
390	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
391	Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. <i>Archives of Osteoporosis</i> , 2020, 15, 119.	2.4	7
392	Transmission of whole body vibration – Comparison of three vibration platforms in healthy subjects. <i>Bone</i> , 2021, 144, 115802.	2.9	7
393	Reassessment Intervals for Transition From Low to High Fracture Risk Among Adults Older Than 50 Years. <i>JAMA Network Open</i> , 2020, 3, e1918954.	5.9	6
394	A surrogate FRAX model for the Kyrgyz Republic. <i>Archives of Osteoporosis</i> , 2020, 15, 68.	2.4	6
395	Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. <i>Osteoporosis International</i> , 2021, 32, 165-171.	3.1	6
396	Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 528-528.	1.6	6

#	ARTICLE	IF	CITATIONS
397	The application of FRAX in Saudi Arabia. Archives of Osteoporosis, 2021, 16, 166.	2.4	6
398	Digital health interventions for osteoporosis and post-fragility fracture care. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210835.	2.7	6
399	Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporosis International, 2022, 33, 1185-1189.	3.1	6
400	Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Archives of Osteoporosis, 2022, 17, 56.	2.4	6
401	Vitamin D and analogues in renal bone disease and implications for osteoporosis. Osteoporosis International, 1997, 7, 179-183.	3.1	5
402	Oral clodronate as treatment of osteogenesis imperfecta. Archives of Disease in Childhood, 2003, 88, 945-945.	1.9	5
403	Modified Calcaneal Index: A New Screening Tool for Osteoporosis Based on Plain Radiographs of the Calcaneum. Journal of Orthopaedic Surgery, 2005, 13, 27-33.	1.0	5
404	Fracture Risk Assessment. , 2013, , 1611-1637.		5
405	Pitfalls in the external validation of FRAX: response to Bolland et al.. Osteoporosis International, 2013, 24, 391-392.	3.1	5
406	Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporosis International, 2020, 31, 457-464.	3.1	5
407	A surrogate FRAX model for Pakistan. Archives of Osteoporosis, 2021, 16, 34.	2.4	5
408	Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporosis International, 2021, 32, 1973-1979.	3.1	5
409	Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 2022, 17, 12.	2.4	5
410	Preventing osteoporotic fractures in older people. Practitioner, 2011, 255, 19-22, 2-3.	0.3	5
411	Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease. Seminars in Arthritis and Rheumatism, 1994, 23, 271.	3.4	4
412	Atypical familial Paget's disease of bone. Joint Bone Spine, 2001, 68, 257-261.	1.6	4
413	Can we treat to target in osteoporosis?. International Journal of Clinical Rheumatology, 2015, 10, 1-4.	0.3	4
414	FRAX-based intervention and assessment thresholds for osteoporosis in Iran. Osteoporosis International, 2019, 30, 2225-2230.	3.1	4

#	ARTICLE	IF	CITATIONS
415	Epidemiology of hip fractures in Bulgaria: development of a country-specific FRAX model. Archives of Osteoporosis, 2020, 15, 28.	2.4	4
416	A country-specific FRAX model for Botswana. Archives of Osteoporosis, 2021, 16, 90.	2.4	4
417	Treatment of Paget's Disease with the New Bisphosphonates. , 1991, , 112-134.		4
418	Contribution of calcium and other dietary components to global variations in bone mineral density in young adults. Food and Nutrition Bulletin, 2002, 23, 180-4.	1.4	4
419	Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Archives of Osteoporosis, 2022, 17, 49.	2.4	4
420	Preliminary study on relationship between vertebral fracture and aortic calcification in postmenopausal women. Journal of Bone and Mineral Metabolism, 1997, 15, 218-222.	2.7	3
421	Osteoporosis management by geriatricians in the UK. Age and Ageing, 2003, 32, 553-553.	1.6	3
422	Expressing fracture risk. Osteoporosis International, 2008, 19, 593-594.	3.1	3
423	Variations in latitude may or may not explain the worldwide variation in hip fracture incidence. Osteoporosis International, 2012, 23, 2401-2402.	3.1	3
424	Automatic Quality Control for Population Imaging: A Generic Unsupervised Approach. Lecture Notes in Computer Science, 2016, , 291-299.	1.3	3
425	Use of FRAX® in men. Joint Bone Spine, 2016, 83, 477-478.	1.6	3
426	<i>The Authors reply</i> : Dual energy X-ray absorptiometry: gold standard for muscle mass? by Scafoglieri et al.. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 788-790.	7.3	3
427	Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporosis International, 2019, 30, 525-526.	3.1	3
428	Personalized estimation of one-year mortality risk after elective hip or knee arthroplasty for osteoarthritis. Bone and Joint Research, 2020, 9, 808-820.	3.6	3
429	Use of an electronic medical record dashboard to identify gaps in osteoporosis care. Archives of Osteoporosis, 2021, 16, 76.	2.4	3
430	Diagnostic Thresholds for Osteoporosis in Men. , 2010, , 605-611.		3
431	Events per person year. BMJ: British Medical Journal, 1995, 310, 1469-1469.	2.3	3
432	Prevalence of FRAX risk factors and the osteoporosis treatment gap among women 70 years of age in routine primary care across 8 countries in Europe. Archives of Osteoporosis, 2022, 17, 20.	2.4	3

#	ARTICLE	IF	CITATIONS
433	Quantitating Age-Related BMD Textural Variation from DXA Region-Free-Analysis: A Study of Hip Fracture Prediction in Three Cohorts. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1679-1688.	2.8	3
434	Treating Paget's disease.. <i>BMJ: British Medical Journal</i> , 1987, 294, 1612-1613.	2.3	2
435	Global variations in peak bone mass as studied by dual-energy X-ray absorptiometry. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2004, 259, 341-345.	1.5	2
436	Prevention of bone loss and management of fracture risk in HIV-infected individuals: case studies and recommendations for different patient subgroups. <i>Future Virology</i> , 2011, 6, 769-782.	1.8	2
437	Pre-screening young postmenopausal women for BMD testing. <i>BoneKey Reports</i> , 2014, 3, 544.	2.7	2
438	Incidence of myocardial infarction and associated mortality varies by latitude and season: findings from a Swedish Registry Study. <i>Journal of Public Health</i> , 2020, 42, e440-e448.	1.8	2
439	FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. <i>Journal of Osteoporosis</i> , 2021, 2021, 1-7.	0.5	2
440	The application of FRAX in Ecuador. <i>Revista Colombiana De ReumatologÃa</i> , 2023, 30, 199-206.	0.1	2
441	A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. <i>Journal of Clinical Oncology</i> , 2004, 22, 8056-8056.	1.6	2
442	Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1117-1124.	2.8	2
443	Trabecular Bone Score Adjustment for the Fracture Risk Assessment Tool (FRAX®). <i>Calcified Tissue International</i> , 2022, 111, 226-227.	3.1	2
444	Population screening for fracture risk in postmenopausal women â€” a logical step in reducing the osteoporotic fracture burden?. <i>Osteoporosis International</i> , 0, , .	3.1	2
445	Calcium metabolism and myeloma and the treatment of hypercalcemia. <i>Hematological Oncology</i> , 1988, 6, 115-117.	1.7	1
446	Effective treatment of malignant hypercalcaemia using a single intravenous infusion of clodronate. <i>Bone and Mineral</i> , 1992, 17, S28.	1.9	1
447	WR-2721 and hypocalcemia.. <i>Journal of Clinical Oncology</i> , 1994, 12, 232-232.	1.6	1
448	Effects of intravenous dichloromethylene bisphosphonate (CL2MBP) in the treatment of Paget's disease of bone. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 23, 270.	3.4	1
449	An unusual cause of pulmonary hypertension and right heart failure.. <i>Postgraduate Medical Journal</i> , 1998, 74, 697-698.	1.8	1
450	Use of Bisphosphonates in the Treatment of Multiple Myeloma. <i>Hematology</i> , 1998, 3, 291-298.	1.5	1

#	ARTICLE	IF	CITATIONS
451	Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis. <i>Sarcoma</i> , 2002, 6, 131-133.	1.3	1
452	The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006. <i>Annals of Oncology</i> , 2007, 18, 393.	1.2	1
453	Identification of vertebral fractures: a moderately severe solution?. <i>Osteoporosis International</i> , 2017, 28, 1853-1855.	3.1	1
454	Towards a toolkit for the assessment and monitoring of musculoskeletal ageing. <i>Age and Ageing</i> , 2018, 47, 774-777.	1.6	1
455	Estimating patient-specific mortality after joint replacement: algorithm development and validation using national audit datasets. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S229.	1.3	1
456	Screening for high fracture risk. <i>Osteoporosis International</i> , 2020, 31, 1179-1180.	3.1	1
457	FRAX-based intervention thresholds for Pakistan. <i>Osteoporosis International</i> , 2022, 33, 105-112.	3.1	1
458	Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. <i>The Canadian Journal of Oncology</i> , 1995, 5 Suppl 1, 54-7.	0.1	1
459	Clodronate in the management of breast cancer and multiple myeloma. <i>Ortopedia Traumatologia Rehabilitacja</i> , 2003, 5, 227-33.	0.3	1
460	FRAX. , 2022, , 89-99.		1
461	FREM predicts 10-year incident fracture risk independent of FRAX [®] probability: a registry-based cohort study. <i>Osteoporosis International</i> , 2022, , 1.	3.1	1
462	Treatment of osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 1993, 11, S17-S24.	2.7	0
463	An Age- and Sex-Controlled Matched Pair Analysis of T Scores in Ethnic Indians with Hip Fractures. <i>Journal of Orthopaedic Surgery</i> , 2004, 12, 133-133.	1.0	0
464	Cost Implications of Bisphosphonates. , 2006, , 415-426.		0
465	Prevention of Bone Loss. , 2006, , 399-414.		0
466	Current status and future prospects in the management of bone disease. <i>Future Rheumatology</i> , 2006, 1, 289-291.	0.2	0
467	Estimates of fracture probability in Denmark. <i>Osteoporosis International</i> , 2007, 18, 1141-1143.	3.1	0
468	Are wrist fractures a good predictor of future fractures, and what are the implications for FRAX [®] ?. <i>IBMS BoneKey</i> , 2010, 7, 254-258.	0.0	0

#	ARTICLE	IF	CITATIONS
469	Is FRAX® a valid screening tool for fragility fracture risk assessment in HIV-positive individuals?. Journal of Infection, 2011, 63, e39-e40.	3.3	0
470	388 CAN LOW RESOLUTION DUAL ENERGY X-RAY ABSORPTIOMETRY IMAGES BE USED TO GRADE OSTEOARTHRITIS SEVERITY?. Osteoarthritis and Cartilage, 2011, 19, S179.	1.3	0
471	Use of FRAX® to target BMD in women <65 years of age. Nature Reviews Endocrinology, 2011, 7, 383-384.	9.6	0
472	Resource Use Related To Vertebral Fractures Based On Data From Icuors. Value in Health, 2014, 17, A48-A49.	0.3	0
473	Bone turnover markers: response to comments by Seeman and Nguyen. Osteoporosis International, 2016, 27, 37-37.	3.1	0
474	A closer look at SCOOP: screening for fracture prevention – Authors' reply. Lancet, The, 2018, 392, 552-553.	13.7	0
475	Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. Annals of Oncology, 2019, 30, v334-v335.	1.2	0
476	Management of bone disease. , 2004, , 319-CP8.		0
477	FRAX®, and the assessment of fracture probability: An introduction. IBMS BoneKey, 2008, 5, 114-117.	0.0	0
478	FRAX I OTsENKA RISK A PERELOMA U MUZhChIN I ZhENShChIN V VELIKOBRI TANI I. Osteoporosis and Bone Diseases, 2008, 11, 38-44.	1.4	0
479	Phosphate binding efficiency of a polyuronic acid in normal subjects. Nephrology Dialysis Transplantation, 1989, 4, 829-30.	0.7	0
480	Calculating fracture risk in primary care. Practitioner, 2010, 254, 7.	0.3	0
481	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
482	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
483	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
484	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
485	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
486	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0